Physician profile
Nancy Ellen Morris
NPI 1265931232
$1,389.69
in general payments reported to CMS, 2019-2025
18 companies · $138 in 2025
The $138 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $393 · 2023: $581 · 2024: $150 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.38 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.73 | 2021-2023 | |
| Astellas Pharma US INC | $155.86 | 2022-2024 | Veozah |
| Lilly USA, LLC | $137.72 | 2022-2023 | Mounjaro |
| Acella Pharmaceuticals, LLC | $137.02 | 2023-2025 | NP Thyroid 60 |
| Amgen INC. | $81.91 | 2023-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $80.77 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $74.07 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $65.32 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.35 | 2022 | |
| Neurocrine Biosciences, INC. | $36.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.11 | 2022 | |
| Urovant Sciences INC | $17.36 | 2022 | |
| Myovant Sciences INC. | $16.96 | 2022 | |
| Avion Pharmaceuticals | $14.65 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $14.46 | 2024 | Ova1 |
| Impel Pharmaceuticals INC. | $13.87 | 2023 | Trudhesa |
| Exeltis, USA INC. | $13.14 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.